Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Conatumumab (DHA29103)

Host species:Human
Isotype:IgG1-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHA29103

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

TRAILR2, TRAIL-R2, Death receptor 5, CD262, DR5, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, TRAIL receptor 2, TRICK2, TNFRSF10B, KILLER, TNF-related apoptosis-inducing ligand receptor 2

Concentration

2.89 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O14763

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

AMG 655, TRAIL-R2mAb, XG1-048 v w, CAS: 896731-82-1

Clone ID

Conatumumab

Data Image
  • SDS-PAGE
    SDS PAGE for Conatumumab
  • Bioactivity
    Detects CD262/TNFRSF10B/TRAIL-R2/DR5 in indirect ELISAs.
References

Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer, PMID: 20496264

Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults, PMID: 21877997

64 Cu-Tetraazacyclododecane- N, N', N'', N'''-tetraacetic acid-conatumumab, PMID: 22220318

Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5, PMID: 21571804

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types, PMID: 20150762

Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery, PMID: 21875750

A first-in-human study of conatumumab in adult patients with advanced solid tumors, PMID: 20947515

Durable Complete Response to AMG 655 (Conatumumab) and Vorinostat in a Patient With Relapsed Classical Hodgkin Lymphoma: Extraordinary Response from a Phase 1b Clinical Protocol, PMID: 32828719

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors, PMID: 21161528

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial, PMID: 24122767

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study, PMID: 22240283

Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling, PMID: 20623688

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer, PMID: 23370314

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer, PMID: 22700995

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab, PMID: 24816908

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer, PMID: 23510984

Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review, PMID: 32770529

The serum protein transthyretin as a platform for dimerization and tetramerization of antibodies and Fab fragments to enable target clustering, PMID: 32518163

Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma, PMID: 26291055

Onto better TRAILs for cancer treatment, PMID: 26943322

Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab, PMID: 22932917

Death receptors as targets in cancer, PMID: 23638798

A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer, PMID: 27806321

99m Tc-Duramycin SPECT Imaging of Early Tumor Response to Targeted Therapy: A Comparison with 18 F-FDG PET, PMID: 27879368

Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations, PMID: 28675660

Therapeutic targeting of the TNF superfamily: a promising treatment for advanced endometrial adenocarcinoma, PMID: 22885470

Gateways to clinical trials, PMID: 19798455

[ 99m Tc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference, PMID: 29031229

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells, PMID: 24909167

Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum, PMID: 22119514

Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer, PMID: 22678353

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity, PMID: 25043603

Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain, PMID: 24083782

American Society of Hematology--51st annual meeting & exposition. Part 1, PMID: 20127549

Leveraging image cytometry for the development of clinically feasible biomarkers: evaluation of activated caspase-3 in fine needle aspirate biopsies, PMID: 21704844

Datasheet

Document Download

Research Grade Conatumumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Conatumumab [DHA29103]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only